following a resubmission assessed under the end of life and orphan equivalent medicine process:
osimertinib (Tagrisso®) is accepted for use within NHSScotland.
Indication under review: As monotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations.
Osimertinib, compared with two other EGFR tyrosine kinase inhibitors, improved progression-free survival in adults with locally advanced or metastatic NSCLC with activating EGFR mutations.
This advice applies only in the context of approved NHSScotland Patient Access Scheme (PAS) arrangements delivering the cost-effectiveness results upon which the decision was based, or PAS/ list prices that are equivalent or lower.
This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.
Medicine details
- Medicine name:
- osimertinib (Tagrisso)
- SMC ID:
- SMC2382
- Indication:
As monotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations.
- Pharmaceutical company
- AstraZeneca UK Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Resubmission
- Status
- Accepted
- Date advice published
- 17 January 2022